Lizzy Smyth
@lizzysmyth.bsky.social
Oncologist. Cancer Research 👩⚕️. Clinical Trials 🧬💊. Oxford Irish. #Oncsky
📢It's #ESMO election time!
I am delighted to be nominated for ESMO Director of Education 😊
ALL the nominees are fantastic representing the global @myesmo.bsky.social community 🌍
🙏for all the good wishes
Rules this year for social media so that's it from me!
Now please vote 🗳️!
I am delighted to be nominated for ESMO Director of Education 😊
ALL the nominees are fantastic representing the global @myesmo.bsky.social community 🌍
🙏for all the good wishes
Rules this year for social media so that's it from me!
Now please vote 🗳️!
May 27, 2025 at 11:19 AM
📢It's #ESMO election time!
I am delighted to be nominated for ESMO Director of Education 😊
ALL the nominees are fantastic representing the global @myesmo.bsky.social community 🌍
🙏for all the good wishes
Rules this year for social media so that's it from me!
Now please vote 🗳️!
I am delighted to be nominated for ESMO Director of Education 😊
ALL the nominees are fantastic representing the global @myesmo.bsky.social community 🌍
🙏for all the good wishes
Rules this year for social media so that's it from me!
Now please vote 🗳️!
We've spent 2024 discussing RT trial results in gastroesophageal cancer.
My radiation oncology mate Som helps me make sense of it all below...
2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change
prac.co/l/22cfph7u
My radiation oncology mate Som helps me make sense of it all below...
2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change
prac.co/l/22cfph7u
2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change
Written by Elizabeth Smyth MD Written by Somnath Mukherjee MD, MRCP, FRCR, FRCP
prac.co
December 11, 2024 at 7:26 PM
We've spent 2024 discussing RT trial results in gastroesophageal cancer.
My radiation oncology mate Som helps me make sense of it all below...
2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change
prac.co/l/22cfph7u
My radiation oncology mate Som helps me make sense of it all below...
2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change
prac.co/l/22cfph7u
Reposted by Lizzy Smyth
When the Western really has to work (via DPhil student text)
Good to see the old methods live on
Good to see the old methods live on
December 9, 2024 at 7:03 PM
When the Western really has to work (via DPhil student text)
Good to see the old methods live on
Good to see the old methods live on
Reposted by Lizzy Smyth
Just published in #ESMOopen results from our trial of IO-naive patients with advanced kidney cancer with PD1/CTLA4 and PD1/LAG3!
www.esmoopen.com/article/S205...
www.esmoopen.com/article/S205...
DEFINE_ME
www.esmoopen.com
December 7, 2024 at 7:52 AM
Just published in #ESMOopen results from our trial of IO-naive patients with advanced kidney cancer with PD1/CTLA4 and PD1/LAG3!
www.esmoopen.com/article/S205...
www.esmoopen.com/article/S205...
Reposted by Lizzy Smyth
Twitter, as we knew it, is gone, stained by new horrific algorithms that promote misinformation.
🦋 is a much better place for those interested in science. And it’s growing fast.
Thanks @jamiedoggett for highlighting our efforts to rebuild a safe place for scientific discussion.
🦋 is a much better place for those interested in science. And it’s growing fast.
Thanks @jamiedoggett for highlighting our efforts to rebuild a safe place for scientific discussion.
Bluesky or X: The role influential HCPs will play in ‘stay, go or double-up’ cannot be underestimated. With #ASH24 and #SABCS2024 just around the corner, this is an interesting moment for health conversation on socials.
@ptarantinomd.bsky.social #MedTwitter #MedSky
www.linkedin.com/pulse/role-h...
@ptarantinomd.bsky.social #MedTwitter #MedSky
www.linkedin.com/pulse/role-h...
The role of health influencers in X vs Bluesky: stay, go or double-up
Since its inception, the modest growth of new social media platform Bluesky Social was not drawing a great deal of attention. The platform was invite-only until February 2024 and since opening up star...
www.linkedin.com
December 4, 2024 at 6:56 PM
Twitter, as we knew it, is gone, stained by new horrific algorithms that promote misinformation.
🦋 is a much better place for those interested in science. And it’s growing fast.
Thanks @jamiedoggett for highlighting our efforts to rebuild a safe place for scientific discussion.
🦋 is a much better place for those interested in science. And it’s growing fast.
Thanks @jamiedoggett for highlighting our efforts to rebuild a safe place for scientific discussion.
Good to see our protocol paper for DECIPHER in press at ESMO GO!
ctDNA 🧬 after surgery will detect pts with HER2➕ gastroesophageal #cancer at high risk of recurring
🧬➕ receive TDxD instead of usual post-op chemo
Hope to #cure some micrometastatic cancers 🙏
www.sciencedirect.com/science/arti...
ctDNA 🧬 after surgery will detect pts with HER2➕ gastroesophageal #cancer at high risk of recurring
🧬➕ receive TDxD instead of usual post-op chemo
Hope to #cure some micrometastatic cancers 🙏
www.sciencedirect.com/science/arti...
Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER
Operable gastrooesophageal adenocarcinoma (GOA) is treated with multimodality therapy which is curative in <50% of patients. Patients in the UK with o…
www.sciencedirect.com
December 1, 2024 at 11:18 AM
Good to see our protocol paper for DECIPHER in press at ESMO GO!
ctDNA 🧬 after surgery will detect pts with HER2➕ gastroesophageal #cancer at high risk of recurring
🧬➕ receive TDxD instead of usual post-op chemo
Hope to #cure some micrometastatic cancers 🙏
www.sciencedirect.com/science/arti...
ctDNA 🧬 after surgery will detect pts with HER2➕ gastroesophageal #cancer at high risk of recurring
🧬➕ receive TDxD instead of usual post-op chemo
Hope to #cure some micrometastatic cancers 🙏
www.sciencedirect.com/science/arti...
Reposted by Lizzy Smyth
Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 30, 2024 at 12:54 PM
Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Lizzy Smyth
OS results of KN-522 out in @NEJM. Terrific news: adding pembro to neoadjuvant chemo for TNBC saves lives (5% 5-year Δ). Bad news: we’re stuck with giving 5 drugs to all patients with stage II-III TNBC, with permanent toxicity for many. Biomarkers, please! t.co/8S9YWOP1lr
November 28, 2024 at 3:08 AM
OS results of KN-522 out in @NEJM. Terrific news: adding pembro to neoadjuvant chemo for TNBC saves lives (5% 5-year Δ). Bad news: we’re stuck with giving 5 drugs to all patients with stage II-III TNBC, with permanent toxicity for many. Biomarkers, please! t.co/8S9YWOP1lr
Nice work from my (ex 😥) fellow @acammarota.bsky.social 👏👏
Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show:
✅Strong link between PD-L1 and pathological response.
✖️ Less so OS ..
www.esmogastro.org/article/S294...
Looking forward to MATTERHORN next year!
Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show:
✅Strong link between PD-L1 and pathological response.
✖️ Less so OS ..
www.esmogastro.org/article/S294...
Looking forward to MATTERHORN next year!
PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials
Perioperative chemoimmunotherapy [i.e. chemotherapy plus immune checkpoint inhibitor
(ICI) (ChT–ICI)] is an investigational treatment for operable gastroesophageal adenocarcinoma
(GEA) with unclear ou...
www.esmogastro.org
November 29, 2024 at 6:28 AM
Nice work from my (ex 😥) fellow @acammarota.bsky.social 👏👏
Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show:
✅Strong link between PD-L1 and pathological response.
✖️ Less so OS ..
www.esmogastro.org/article/S294...
Looking forward to MATTERHORN next year!
Examining PD-L1 expression in RCTs of chemo vs. chemo-ICI in operable GEA we show:
✅Strong link between PD-L1 and pathological response.
✖️ Less so OS ..
www.esmogastro.org/article/S294...
Looking forward to MATTERHORN next year!
Reposted by Lizzy Smyth
www.nature.com/articles/s41...
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Next-generation combination approaches for immune checkpoint therapy - Nature Immunology
In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.
www.nature.com
November 25, 2024 at 8:43 PM
www.nature.com/articles/s41...
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Reposted by Lizzy Smyth
Regular abstracts from #SABCS24 are out!
3407 pages of new breast cancer discoveries.
Find them here: sabcs.org/Portals/0/Do...
3407 pages of new breast cancer discoveries.
Find them here: sabcs.org/Portals/0/Do...
sabcs.org
November 25, 2024 at 11:41 PM
Regular abstracts from #SABCS24 are out!
3407 pages of new breast cancer discoveries.
Find them here: sabcs.org/Portals/0/Do...
3407 pages of new breast cancer discoveries.
Find them here: sabcs.org/Portals/0/Do...
Reposted by Lizzy Smyth
ASCO annual meeting 2025 abstract submitter open - closes Jan 28th.
To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)!
Apply for a waiver when you submit an abstract
conferences.asco.org/am/abstract-...
To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)!
Apply for a waiver when you submit an abstract
conferences.asco.org/am/abstract-...
ASCO Meetings
conferences.asco.org
November 23, 2024 at 3:10 PM
ASCO annual meeting 2025 abstract submitter open - closes Jan 28th.
To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)!
Apply for a waiver when you submit an abstract
conferences.asco.org/am/abstract-...
To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)!
Apply for a waiver when you submit an abstract
conferences.asco.org/am/abstract-...
Best case series ever 🤣..
Wishing the Elsevier editors who desk-accepted this all the best for their next career moves.
doi.org/10.1016/j.ij...
doi.org/10.1016/j.ij...
November 23, 2024 at 12:58 PM
Best case series ever 🤣..
Looking forward to seeing the other institutions & societies join too...
I've been lobbying mine 🙂
I've been lobbying mine 🙂
November 23, 2024 at 11:27 AM
Looking forward to seeing the other institutions & societies join too...
I've been lobbying mine 🙂
I've been lobbying mine 🙂
Reposted by Lizzy Smyth
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody
drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC
internalization. The additi...
www.cell.com
November 12, 2024 at 12:33 PM
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
Reposted by Lizzy Smyth
@valdesan.bsky.social to the rescue! Oncology Vol 1 and 2 starter packs (links included in the packs)
go.bsky.app/UP8aWPd
#medsky #oncsky #oncosky #oncology
go.bsky.app/UP8aWPd
#medsky #oncsky #oncosky #oncology
November 23, 2024 at 7:06 AM
@valdesan.bsky.social to the rescue! Oncology Vol 1 and 2 starter packs (links included in the packs)
go.bsky.app/UP8aWPd
#medsky #oncsky #oncosky #oncology
go.bsky.app/UP8aWPd
#medsky #oncsky #oncosky #oncology
Good new for BTC patients!
Zanidatamab receives accelerated #FDAapproval for previously untreated unresectable or advanced HER2+ biliary tract cancer based on the single arm HERIZON-BTC-01 trial showing an ORR of 52% and median DOR of 14.9 mo #BTC @fda.gov #OncSky #CanSky #MedSky bit.ly/3CBbOoz
FDA grants accelerated approval to zanidatamab-hrii
On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.) for biliary tract cancer.
bit.ly
November 22, 2024 at 4:14 PM
Good new for BTC patients!
Reposted by Lizzy Smyth
‘A place of joy’: why scientists are joining the rush to Bluesky
‘A place of joy’: why scientists are joining the rush to Bluesky
Researchers say the social-media platform — an alternative to X — offers more control over the content they see and the people they engage with.
www.nature.com
November 22, 2024 at 2:19 PM
November 22, 2024 at 8:49 AM
Reposted by Lizzy Smyth
November is gastric cancer awareness month and we are sharing updates in the field ⭐
At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.
👉See the video below! 👈
https://buff.ly/48WQh5R
#stcsm #gism
At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.
👉See the video below! 👈
https://buff.ly/48WQh5R
#stcsm #gism
Long-term survivorship concerns of patients with esophageal and gastric cancer - VJOncology
Jessie Elliott, FRCS, PhD, Trinity St. James’s Cancer Institute, Dublin, Ireland, discusses the long-term survivorship concerns of patients with esophageal...
buff.ly
November 20, 2024 at 9:01 AM
November is gastric cancer awareness month and we are sharing updates in the field ⭐
At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.
👉See the video below! 👈
https://buff.ly/48WQh5R
#stcsm #gism
At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.
👉See the video below! 👈
https://buff.ly/48WQh5R
#stcsm #gism
Better late than never 😊👍!
The blue plaque which commemorates the celebration of the discovery of the structure of DNA has finally been updated to acknowledge Rosalind Franklin. #womeninSTEM
😍
newn.cam.ac.uk/newnham-news...
😍
newn.cam.ac.uk/newnham-news...
November 21, 2024 at 10:17 AM
Better late than never 😊👍!
Reposted by Lizzy Smyth
Right on time for #NANETS2024: the North American Neuroendocrine Tumor Society is on @bsky.app ! Lots of posts to come from the NET community over the next three days during the Annual Symposium taking place in #Chicago. @oncothor.bsky.social @cancertrials.bsky.social @halletjulie.bsky.social
November 21, 2024 at 2:33 AM
Right on time for #NANETS2024: the North American Neuroendocrine Tumor Society is on @bsky.app ! Lots of posts to come from the NET community over the next three days during the Annual Symposium taking place in #Chicago. @oncothor.bsky.social @cancertrials.bsky.social @halletjulie.bsky.social
Reposted by Lizzy Smyth
🚨The exodus of #MedTwitter #OncSky to #BlueSky @bsky.app is fascinating. All the #Twitter birds are now flying freely in the Bluesky. 🐦💙 Will #Bluesky succeed where #Threads and #Mastodon struggled?#MedTwitterMigration #BlueSkySocial @oncoalert.bsky.social @tmprowell.bsky.social
November 19, 2024 at 2:01 AM
🚨The exodus of #MedTwitter #OncSky to #BlueSky @bsky.app is fascinating. All the #Twitter birds are now flying freely in the Bluesky. 🐦💙 Will #Bluesky succeed where #Threads and #Mastodon struggled?#MedTwitterMigration #BlueSkySocial @oncoalert.bsky.social @tmprowell.bsky.social
❓ Should we switch chemotherapy for patients with gastroesophageal cancer after 3 months?
ARMANI trial published in Lancet Oncol today
✔️ Patients who switched to 2L pac/ram after 3m of OxFU had ⬆️ PFS and OS than patients who continued 1L chemo
❌....but also ⬆️ hospital visits & toxicity.
November 19, 2024 at 4:25 PM
❓ Should we switch chemotherapy for patients with gastroesophageal cancer after 3 months?
ARMANI trial published in Lancet Oncol today
✔️ Patients who switched to 2L pac/ram after 3m of OxFU had ⬆️ PFS and OS than patients who continued 1L chemo
❌....but also ⬆️ hospital visits & toxicity.
@lizzysmyth.bsky.social added you to this list. Please share and spread the word. go.bsky.app/GKXp9Fy
November 16, 2024 at 5:21 PM